Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Rebecca Leyland"'
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Programmed death-ligand 1 (PD-L1) is an immune checkpoint inhibitor that binds to its receptor PD-1 expressed by T cells and other immune cells to regulate immune responses; ultimately preventing exacerbated activation and autoimmunity. Many tumors e
Externí odkaz:
https://doaj.org/article/f65c4066da144be3989cafa99f077a9e
Autor:
Emily C. Sheppard, Rikke Brandstrup Morrish, Michael J. Dillon, Rebecca Leyland, Richard Chahwan
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
Epigenetic modifications, such as histone modifications, DNA methylation status, and non-coding RNAs (ncRNA), all contribute to antibody maturation during somatic hypermutation (SHM) and class-switch recombination (CSR). Histone modifications alter t
Externí odkaz:
https://doaj.org/article/abe6d84d96a94abeb76b61585d83da01
Autor:
Robert W. Wilkinson, Simon J. Dovedi, Ross Stewart, Viia Valge-Archer, Michelle Morrow, James A. Harper, Hazel Jones, Matthew McCourt, Brandon W. Higgs, Philip Brohawn, Jane Coates Ulrichsen, Amanda Watkins, Judith Anderton, Danielle Marcus, Luciano Pacelli, Stefanie Mullins, Rebecca Leyland, Miika J. Ahdesmaki, Danielle M. Greenawalt, Dennis Y.Q. Wang, Jens-Oliver Koopmann, Richard C.A. Sainson, John E. Prime, Suzanne I.S. Mosely
Murine syngeneic tumor models are critical to novel immuno-based therapy development, but the molecular and immunologic features of these models are still not clearly defined. The translational relevance of differences between the models is not fully
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::adcb199105c771e6b82b33f00095d352
https://doi.org/10.1158/2326-6066.c.6548411.v1
https://doi.org/10.1158/2326-6066.c.6548411.v1
Autor:
Robert W. Wilkinson, Simon J. Dovedi, Ross Stewart, Viia Valge-Archer, Michelle Morrow, James A. Harper, Hazel Jones, Matthew McCourt, Brandon W. Higgs, Philip Brohawn, Jane Coates Ulrichsen, Amanda Watkins, Judith Anderton, Danielle Marcus, Luciano Pacelli, Stefanie Mullins, Rebecca Leyland, Miika J. Ahdesmaki, Danielle M. Greenawalt, Dennis Y.Q. Wang, Jens-Oliver Koopmann, Richard C.A. Sainson, John E. Prime, Suzanne I.S. Mosely
Supplementary Figure S1: Summary of experiments Supplementary Figure S2: Gating strategy Supplementary Figure S3:Profiling by array CGH, whole-exome and targeted sequencing Supplementary Figure S4: Comparison of mutational profiles of murine syngenei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f963acbe001e8dcef590d845d2ff257
https://doi.org/10.1158/2326-6066.22537352.v1
https://doi.org/10.1158/2326-6066.22537352.v1
Autor:
Robert W. Wilkinson, Simon J. Dovedi, Ross Stewart, Viia Valge-Archer, Michelle Morrow, James A. Harper, Hazel Jones, Matthew McCourt, Brandon W. Higgs, Philip Brohawn, Jane Coates Ulrichsen, Amanda Watkins, Judith Anderton, Danielle Marcus, Luciano Pacelli, Stefanie Mullins, Rebecca Leyland, Miika J. Ahdesmaki, Danielle M. Greenawalt, Dennis Y.Q. Wang, Jens-Oliver Koopmann, Richard C.A. Sainson, John E. Prime, Suzanne I.S. Mosely
Supplementary dataset containing raw data from targeted sequencing, whole exome sequencing, array CGH and transcriptomic analysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94215efbd254285ab59554f7efa849cb
https://doi.org/10.1158/2326-6066.22537355
https://doi.org/10.1158/2326-6066.22537355
Autor:
Ross Stewart, Robert W. Wilkinson, Ching Ching Leow, Athula Herath, Philip Mallinder, Scott A. Hammond, Michelle Morrow, Lesley Young, Kelly McGlinchey, David A. Leinster, Jane Coates Ulrichsen, Michael D. Oberst, Stefanie Mullins, Li Yan, John Andrews, Emily Offer, Natalie J. Tigue, Lisa Bamber, Nicholas Holoweckyj, Kathy A. Mulgrew, Amanda Watkins, Rebecca Leyland
Additional materials and methods and supplementary figure legends with tracked changes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::671e099e5f25fb580caea686b8b7f676
https://doi.org/10.1158/1078-0432.22463777.v1
https://doi.org/10.1158/1078-0432.22463777.v1
Autor:
Ross Stewart, Robert W. Wilkinson, Ching Ching Leow, Athula Herath, Philip Mallinder, Scott A. Hammond, Michelle Morrow, Lesley Young, Kelly McGlinchey, David A. Leinster, Jane Coates Ulrichsen, Michael D. Oberst, Stefanie Mullins, Li Yan, John Andrews, Emily Offer, Natalie J. Tigue, Lisa Bamber, Nicholas Holoweckyj, Kathy A. Mulgrew, Amanda Watkins, Rebecca Leyland
Supplementary figures S1-4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::697d83739c7675c2a3405246bc4a4539
https://doi.org/10.1158/1078-0432.22463783.v1
https://doi.org/10.1158/1078-0432.22463783.v1
Autor:
Ross Stewart, Robert W. Wilkinson, Ching Ching Leow, Athula Herath, Philip Mallinder, Scott A. Hammond, Michelle Morrow, Lesley Young, Kelly McGlinchey, David A. Leinster, Jane Coates Ulrichsen, Michael D. Oberst, Stefanie Mullins, Li Yan, John Andrews, Emily Offer, Natalie J. Tigue, Lisa Bamber, Nicholas Holoweckyj, Kathy A. Mulgrew, Amanda Watkins, Rebecca Leyland
Purpose: To generate and characterize a murine GITR ligand fusion protein (mGITRL-FP) designed to maximize valency and the potential to agonize the GITR receptor for cancer immunotherapy.Experimental Design: The EC50 value of the mGITRL-FP was compar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a7e495d8f0b024911cdaaba2097a9fc
https://doi.org/10.1158/1078-0432.c.6525515
https://doi.org/10.1158/1078-0432.c.6525515
Autor:
Ross Stewart, Robert W. Wilkinson, Ching Ching Leow, Athula Herath, Philip Mallinder, Scott A. Hammond, Michelle Morrow, Lesley Young, Kelly McGlinchey, David A. Leinster, Jane Coates Ulrichsen, Michael D. Oberst, Stefanie Mullins, Li Yan, John Andrews, Emily Offer, Natalie J. Tigue, Lisa Bamber, Nicholas Holoweckyj, Kathy A. Mulgrew, Amanda Watkins, Rebecca Leyland
Additional materials and methods and supplementary figure legends.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d03ee0abf1e2c2c527f5f5b6e61da07
https://doi.org/10.1158/1078-0432.22463780.v1
https://doi.org/10.1158/1078-0432.22463780.v1
Autor:
Nicholas M. Durham, Ruth Franks, Christel Navarro, Kelly McGlinchey, Hong Jin, Nicola Rath, Robert W. Wilkinson, James Harper, Andrew Leinster, Rebecca Leyland, Xing Cheng, Simon J. Dovedi, Kathy Mulgrew, Lee Brown, Jon Travers, Jens-Oliver Koopmann, Shannon Burke, Danielle Carroll, Jim Eyles
Publikováno v:
Molecular Cancer Therapeutics. 20:1723-1734
A recombinant Newcastle Disease Virus (NDV), encoding either a human (NDVhuGM-CSF, MEDI5395) or murine (NDVmuGM-CSF) GM-CSF transgene, combined broad oncolytic activity with the ability to significantly modulate genes related to immune functionality